Categories
Connect with us on LinkedIn
Build vs. Buy vs. Partner in Life Sciences: Making the Right Call
How do you decide between building, buying, or partnering? Learn key decision factors and red flags to avoid...
Do CROs Need to Reinvent Themselves in 2025? A Deep Dive with Greg Licholai and Derk Arts
High R&D costs aren’t due to a lack of innovation but inefficiencies in trials. Here’s how we can...
Clinical Trials Aren’t Just About Patients (and That’s Okay)
This article explores the debate between patient-centricity and protocol-centricity in clinical trials, featuring insights from Derk Arts (Castor)...
Strategies to Minimize Participant and Healthcare Provider Burden in Clinical Trials
This article examines strategies to reduce participant and provider burden in clinical trials while ensuring high-quality data collection....
What do we measure with PROs in head and neck cancer? Pain, QoL, adverse events and more
Patient-Reported Outcomes (PROs) are essential in head and neck cancer research, offering insights into symptoms, quality of life,...
A New Perspective on Clinical Research: Accessibility and Innovation
Joost Rigter’s inspiring journey highlights the importance of accessibility in clinical research. From AI-driven tools to simplified communication,...
Local Labs in the EDC: Streamlining Safety and Efficacy Insights
Local labs are a vital part of clinical trials, offering fast, cost-effective insights into safety and efficacy. But...
Beyond Compliance: How Quality Culture Drives Clinical Trial Excellence
Moving beyond compliance, quality culture drives clinical trial innovation through automated processes and measurable results.
eCOA Evolution: Have We Overcomplicated What Used to Work?
A blueprint for engineering elegant eCOA solutions that make complex trials feel simple.
Waiver of Consent vs Waiver of Written Consent
One is very common, the other is rarely granted. Learn the key differences between waiver of consent &...
Unlocking FDA’s Vision for PRO Collection in RWE: Timing, Methods, and Insights
Discover FDA's guidance on collecting PROs for Real-World Evidence (RWE), focusing on timing, methods, and improving data quality.
Understanding Phase 4 Clinical Trials: A Critical Component of Post-Marketing Insight to Drugs in the Real-World
When it comes to Phase 4 clinical trials, Castor's cutting-edge Real-World Evidence (RWE) platform is your key to...
5 Key Takeaways from the FDA’s Real-World Evidence Guidance
A deep dive into the evolving regulatory environment, the innovative approaches emerging in RWE, and the critical importance...
Navigating the Evolving Regulatory and Data Landscape
A deep dive into the evolving regulatory environment, the innovative approaches emerging in RWE, and the critical importance...
Do We Still Need Patients in Tomorrow’s Trials? Modeling Placebo Effect and Beyond
Discover the transformative role of AI in clinical trials, with expert insights from Derk Arts and MaryAnne Rizk...
eCOA: Afterthought or Essential Strategy? An Expert’s View on Choosing and Developing an eCOA Strategy
The Evolving Landscape of eCOA in Clinical Trials Clinical trials have long grappled with the complexities of data...
Evaluating “Bother” as a Component of Patient-Reported Outcomes in Clinical Studies
Patient-reported outcome (PRO) instruments refer to multiple scales and questionnaires designed to collect patients’ personal feedback on their...
Revolutionizing Blood Pressure Monitoring: Insights from Aktiia and Castor’s Collaboration
How Aktiia brought their continuous BP device to market by integrating vast amounts of blood pressure data with...
Connect with us on LinkedIn
